Topical targeting therapies for sexually transmitted diseases

Current Nanoscience

Volumn 8, Issue 4, 2012, Pages 486-490

  Andreani, Tatiana ^a,b,c   Macedo, Ana Sofia ^a   Ferreira, Sandra F ^a   Silva, Amélia M ^b,c   Rosmaninho, Aristóteles ^d   Souto, Eliana B ^a,b  

^a UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^b UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^c UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^d HOSPITAL DE SANTO ANTÓNIO   (Portugal)

Author keywords

Diagnostics; Nanotechnology; Prevention; Sexual transmitted diseases; Topical therapy

Indexed keywords

CHEMICAL PROTECTION; PREVENTION; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SKIN DISEASE; TOPICAL DRUGS; TOPICAL THERAPY; TOPICAL TREATMENTS;

DIAGNOSIS; DISEASE CONTROL; DRUG INTERACTIONS; HEALTH CARE; NANOTECHNOLOGY; PLASMA DIAGNOSTICS;

DISEASES;

ACICLOVIR; ANTIVIRUS AGENT; CANDID V; CARBOMER; CLOTRIMAZOLE; DELAVIRDINE; NANOMATERIAL; PENCICLOVIR; RILPIVIRINE; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; VIVAGEL; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DISEASE TRANSMISSION; HEALTH CARE; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NANOTECHNOLOGY; PREGNANCY; PRIORITY JOURNAL; SEXUAL HEALTH; SEXUALLY TRANSMITTED DISEASE; SKIN; TOPICAL DRUG ADMINISTRATION; VAGINA CANDIDIASIS;

EID: 84863891889     PISSN: 15734137     EISSN: 18756786     Source Type: Journal    
DOI: 10.2174/157341312801784348     Document Type: Article

References (76)

1. Paavonen, J. Sexually transmitted chlamydial infections and subfertility. Int. Congr. Ser., 2004, 1266, 277-286.
2. Brown, T.J.; Yen-Moore, A.; Tyring, S. K. An overview of sexually transmitted diseases. Part I. J. Am. Acad. Dermatol., 1999, 41, 511-529.
3. Manavi, K. A review on infection with Chlamydia trachomatis. Best Pract. Res. Clin. Obs. Gyn., 2006, 20 (6), 941-951.
4. Toti, U.S.; Guru, B.R.; Hali, M.; McPharlin, C.M.; Wykes, S.M.; Panyam, J.; Whittum-Hudson, J.A. Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles. Biomaterials, 2011, 32, 6606-6613.
5. Singh, R.; Verma, R.; Kaushik, A.; Sumana, G.; Sood, S.; Gupta, R.K.; Malhotra, B.D. Chitosan-iron oxide nano-composite platform for mismatchdiscriminating DNA hybridization for Neisseria gonorrhoeae detection causing sexually transmitted disease. Biosens. Bioelectron., 2011, 26, 2967-2974.
6. Singh, R.; Sumana, G.; Verma, R.; Sood, S.; Pandey, M.K.; Gupta, R.K.; Malhotra, B.D. DNA biosensor for detection of Neisseria gonorrhoeae causing sexually transmitted disease. J. Biotechnol., 2010, 150 (3), 357-365.
7. UNAIDS UNAIDS report on the global AIDS epidemic; 2010; pp 4-208.
8. Buckheit, R. W. Jr.; Watson, K.M.; Morrow, K.M.; Ham, A.S. Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res., 2010, 85 (1), 142-158.
9. Harris, P.S.; Saag, M.S. Relationships Between Sexually Transmitted Diseases and Human Immunodeficiency Virus Infection. In: Current Problems in Dermatology, Mosby: 1997; Vol. 9, pp 209-236.
10. Neves, J.D.; Amiji, M.M.; Bahia, M.F.; Sarmento, B. Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv. Drug Deliv. Rev., 2010, 62, 458-477.
11. Gupta, U.; Jain, N.K. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv. Drug Deliv. Rev., 2010, 62, 478-490.
12. Severson, J.L.; Tyring, S.K. Viral Disease Update. In: Current Problems in Dermatology, Mosby: 1999; Vol. 11, pp 60-70.
13. Techakehakij, W.; Feldman, R.D. Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: A literature review. Vaccine, 2008, 26, 6258-6265.
14. Dizon, D.S.; Krychman, M.L. Questions & Answers About Human Papilloma Virus (HPV). Jones and Bartlett Publishers: 2011.
15. Paraskevaidis, E.; Arbyn, M.; Sotiriadis, A.; Diakomanolis, E.; Martin-Hirsch, P.; Koliopoulos, G.; Makrydimas, G.; Tofoski, J.; Roukos, D.H. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat. Rev., 2004, 30, 205-211.
16. Hauck, T.S.; Giri, S.; Gao, Y.; Chan, W.C.W. Nanotechnology diagnostics for infectious diseases prevalent in developing countries. Adv. Drug Deliv. Rev., 2010, 62, 438-448.
17. Schäfer-Korting, M.; Mehnert, W.; Korting, H.C. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv. Drug Deliv. Rev., 2007, 59, 427-443.
18. De, M.; Ghosh, P.S.; Rotello, V.M. Applications of nanoparticles in biology. Adv. Mater., 2008, 20, 4225-4241.
19. Munusamy, P.; Seleem, N.S.; Alqublan, H.; Tyler Jr., R.; Sriranganathan, N.; Pickrell, G. Targeted drug delivery using silica xerogel systems to treat diseases due to intracellular pathogens. Mater. Sci. Eng. C., 2009, 29, 2313-2318.
20. O'Farrell, N.; Houlton, A.; Horrocks, B.R. Silicon nanoparticles: applications in cell biology and medicine. Int. J. Nanomed., 2006, 1 (4), 451-472.
21. Pontinha, A.D.R.; Jorge, S.M.A.; Paquim, A.M.C.; Diculescu, V.C.; Oliveira-Brett, A.M. In situ evaluation of anticancer drug methotrexate-DNA interaction using a DNA-electrochemical biosensor and AFM characterization. Phys. Chem. Chem. Phys., 2011, 13, 5227-5234.
22. Taylor, R.F.; Schultz, J.S. Handbook of Chemical and Biological Sensors. Institute of Physics Publishing: Bristol, UK, 1996.
23. Abu-Salah, K.M.; Alrokyan, S.A.; Khan, M.N.; Ansari, A.A. Nanomaterials as Analytical Tools for Genosensors. Sensors, 2010, 10, 963-993.
24. Abu-Salah, K.M.; Ansari, A.A.; Alrokayan, S.A. DNA-Based Applications in Nanobiotechnology. J. Biomed. Biotechnol., 2010, 2010, Article ID 715295, 15 pages doi:10.1155/2010/715295.
25. Bassiri, M.; Mardh, P.A.; Domeika, M. Multiplex AMPLICOR PCR screening for Chlamydia trachomatis and Neisseria gonorrhoeae in women attenting non-sexually transmitted disease clinics. The European Chlamydia Epidemiology Group. J. Clin. Microbiol., 1997, 35(10), 2556-2560.
26. Wang, J. From DNA biosensors to gene chips. Nucleic Acids Res., 2000, 28 (16), 3011-3016.
27. Ansari, A.A.; Singh, R.; Sumana, G.; Malhotra, B.D. Sol-gel derived nanostructured zinc oxide film for sexually transmitted disease sensor. The Analyst, 2009, 134 (5), 997-1002.
28. Yu, H. Use of Immunomagnetic Carriers for the Rapid Detection of Virulent Bacteria from Biological Samples. In Scientific and clinical application of magnetic carriers, Häfeli, U.; Schütt, W.; Teller, J.; Zborowski, M. (Ed), PLENUM Press: 1997, New York.
29. 3 and ZnO nanoparticles. Nanotoxicology, 2011. doi:10.3109/17435390.2011.625131.
30. Mukenge-Tshibaka, L.; Alary, M.; Bernier, F.; van Dyck, E.; Lowndes, C.M.; Guédou, A.; Anagonou, S.; Joly, J.R. Diagnostic Performance of the Roche AMPLICOR PCR in Detecting Neisseria gonorrhoeae in Genitourinary Specimens from Female Sex Workers in Cotonou, Benin. J. Clin. Microbiol., 2000, 38(11), 4076-4079.
31. Jung, C.; Chung, J.W.; Kim, U.O.; Kim, M.H.; Park, H.G. Real-time colorimetric detection of target DNA using isothermal target and signaling probe amplification and gold nanoparticle cross-linking assay. Biosens. Bioelectron., 2011, 26, 1953-1958.
32. Jung, Y.L.; Jung, C.; Parab, H.; Li, T.; Park, H.G. Direct colorimetric diagnosis of pathogen infections by utilizing thiol-labeled PCR primers and unmodified gold nanoparticles. Biosens. Bioelectron., 2010, 25, 1941-1946.
33. Zhao, W.; Chiuman, W.; Lam, J.C.; McManus, S.A.; Chen, W.; Cui, Y.; Pelton, R.; Brook, M.A.; Li, Y. DNA aptamer folding on gold nanoparticles: from colloid chemistry to biosensors. J. Am. Chem. Soc., 2008, 130(11), 3610-3618.
34. Pragya, S.; Rishein, G.; Hem, C.J.; Rajneesh, J.; Apurb, R.B.; Sudha, S.; Aruna, M. Serovar-specific immune responses to peptides of variable regions of Chlamydia trachomatis major outer membrane protein in serovar D infected women. Clin. Exp. Med., 2008, 8, 207-215.
35. Tang, J.; Xu, Z.; Zhou, L.; Qin, H.; Wang, Y.; Wang, H. Rapid and simultaneous detection of Ureaplasma parvum and Chlamydia trachomatis antibodies based on visual protein microarray using gold nanoparticles and silver enhancement. Diagn. Microbiol. Infect. Dis., 2010, 67 (2), 122-128.
36. Sendid, B.; Francois, N.; Standaert, A., Dehecq, E., Zerimech, F., Camus, D., Poulain, D. Prospective evaluation of the new chromogenic medium CandiSelect 4 for differentiation and presumptive identification of the major pathogenic Candida species. J. Med. Microbiol., 2007, 56, 495-499.
37. Sobel, J.D., Candidal vulvovaginitis. Clin. Obstet. Gyn., 1997, 36, 153-212.
38. Calugi, C.; Trabocchi, A.; Guarna, A. Novel small molecules for the treatment of infections caused by Candida albicans: a patent review (2002-2010). Expert Opin. Ther. Pat., 2011, 21 (3), 381-397.
39. Darby, G. Acyclovir and beyond. J. Int. Med. Res., 1994, 22, (Suppl 1), 33A-42A.
40. Andrei, G.; Clercq, E.D.; Snoeck, R. In vitro selection of drug-resistant varicella zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir. Antiviral Res., 2004, 61, 181-187.
41. Jenning, V.; Gohla, S.H., Encapsulation of retinoids in solid lipid nanoparticles. J. Microencapsul., 2001, 18, 149-158.
42. Aji Alex, M.R.; Chacko, A. J.; Jose, S.; Souto, E.B. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur. J. Pharm. Sci., 2011, 42, 11-18.
43. Lv, Q.; Yu, A.; Xi, Y.; Li, H.; Song, Z.; Cui, J.; Cao, F.; Zhai, G. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int. J. Pharm., 2009, 372, 191-198.
44. Jain, S.; Mistry, M.A.; Swarnakar, N.K. Enhanced dermal delivery of acyclovir using solid lipid nanoparticles. Drug Deliv. Transl. Res., 2011, 1, 395-406.
45. Zhu, W.W.; Yu, A.H.; Wang, W.H.; Dong, R.Q.; Wu, J.; Zhai, G.X. Formulation design of microemulsion for dermal delivery of penciclovir. Int. J. Pharm., 2008, 360, 184-190.
46. Kirjavainen, M.; Mönkkönen, J.; Saukkosaari, M.; Valjakka-Koskela, R.; Kiesvaara, J.; Urtti, A., Phospholipids affect stratum corneum lipid bilayer fluidity and drug partitioning into the bilayers. J. Control. Release, 1999, 58, 207-214.
47. El Maghraby, G.M.; Barry, B.W.; Williams, A.C. Liposomes and skin: from drug delivery to model membranes. Eur. J. Pharm. Sci., 2008, 34(4-5), 203-222.
48. Hasanovic, A.; Hollick, C.; Fischinger, K.; Valenta, C. Improvement in physicochemical parameters of DPPC liposomes and increase in skin permeation of aciclovir and minoxidil by the addition of cationic polymers. Eur. J. Pharm. Biopharm., 2010, 75, 148-153.
49. Rojanasakul, Y.; Wang, L.Y.; Bhat, M.; Glover, D.D.; Malagna, C.J.; Ma, J.K.H. The transport barrier of epithelia: a comparative study on membrane permeability and charge selectivity in the rabbit. Pharm. Res., 1992, 9, 1029-1034.
50. Amiji, M.M.; Vyas, T.K.; Shah, L.K. Role of nanotechnology in HIV/AIDS treatment: potential to overcome the viral reservoir challenge. Discov. Med., 2006, 6, 157-162.
51. Tymchuk, C.N.; Currier, J.S. The safety of antiretroviral drugs. Expert Opin. Drug Saf., 2008, 7, 1-4.
52. Souto, E.B.; Doktorovová, S. Solid Lipid Nanoparticle (SLN) Formulations: Pharmacokinetic and Biopharmaceutical Aspects in Drug Delivery. In Methods in Enzymology: Liposomes, Nejat Düzgüne (Ed.), Elsevier Science: 2009; Vol. 464, pp 105-129.
53. Kuo, Y.C.; Su, F.L. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate methyl methacrylate sulfopropyl methacrylate and solid lipid nanoparticles. Int. J. Pharm., 2007, 340, 143-152.
54. Jain, S.; Tiwary, A. K.; Jain, N. K., PEGylated elastic liposomal formulation for lymphatic targeting of zidovudine. Curr. Drug Deliv., 2008, 5, 275-281.
55. Baerta, L.; van't Kloostera, G.; Dries, W.; François, M.; Wouters, A.; Basstanie, E.; Iterbeke, K.; Stappers, F.; Stevens, P.; Schueller, L.; Van Remoortere, P.; Kraus, G.; Wigerinck, P.; Rosier, J. Development of a longacting injectable with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur. J. Pharma. Biopharm., 2009, 72, 502-508.
56. Coordinating Committee of the Global HIV/AIDS Vaccine Enterprise. The Global HIV/AIDS Vaccine Enterprise: Scientific Strategic Plan. PLoS Med., 2005, 2(2), e25. doi:10.1371/journal.pmed.0020025.
57. Weller, S.; Davis, K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst. Rev., 2002, 1, CD003255. doi: 10. 1002/14651858. CD0 03 25 5.
58. UNAIDS, Joint United Nations Programme on HIV/AIDS (UNAIDS). Report on the global AIDS epidemic. 2008.
59. Cutler, B.; Justman, J., Vaginal microbicides and the prevention of HIV transmission. Lancet Infect. Dis., 2008, 8, 685-697.
60. Severy, L.J.; Tolley, E.; Woodsong, C.; Guest, G. A framework for examining the sustained acceptability of microbicides. AIDS Behav., 2005, 9, 121-131.
61. Abdool Karim, Q.; Abdool Karim, S.S.; Frohlich, J.A.; Grobler, A.C.; Baxter, C.; Mansoor, L.E.; Kharsany, A.B.; Sibeko, S.; Mlisana, K.P.; Omar, Z.; Gengiah, T.N.; Maarschalk, S.; Arulappan, N.; Mlotshwa, M.; Morris, L.; Taylor, D. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science, 2010, 329, 1168-1174.
62. Lee, V.H.L. Enzymatic barriers to peptides and protein absorption. CRC Crit. Rev. Ther. Drug Carr. Syst., 1988, 5, 69-98.
63. Yoo, J. W.; Giri, N.; Lee, C.H. pH-sensitive Eudragit nanoparticles for mucosal drug delivery. Int. J. Pharm., 2011, 403, 262-267.
64. Tian, J.; Wong, K.K.; Ho, C.M.; Lok, C.N.; Yu, W.Y.; Che, C.M.; Chiu, J. F.; Tam, P.K. Topical delivery of silver nanoparticles promotes wound healing. Chem. Med. Chem., 2007, 2, 129-136.
65. Lara, H.H.; Ixtepan-Turrent, L.; Garza-Treviño, E.N.; Rodriguez-Padilla, C., Research PVP-coated silver nanoparticles block the transmission of cell-free and cell-associated HIV-1 in human cervical culture. J. Nanobiotechnol., 2010, 13, 8-15.
66. Ham, A.S.; Cost, M.R.; Sassi, A.B.; Dezzutti, C.S.; Rohan, L.C. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm. Res., 2009, 26 (3), 502-511.
67. Woodrow, K.A.; Cu, Y.; Booth, C.J.; Saucier-Sawyer, J.K.; Wood, M.J.; Saltzman, W.M. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat. Mater., 2009, 8, 526-533.
68. Alukda, D.; Sturgis, T.; Youan, B.C. Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention. J. Pharm. Sci., 2011, 100(8), 3345-3356.
69. Meng, J.; Sturgis, T.F.; Youan, B.B. Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion. Eur. J. Pharm. Sci., 2011, 44(1-2), 57-67.
70. Rupp, R.; Rosenthal, S.L.; Stanberry, L.R. VivaGel™ (SPL7013 Gel): A candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int. J. Nanomed., 2007, 2(4), 561-566.
71. Tomalia, D.A.; Baker, H.; Dewald, J.R.; Hall, M.; Kallos, G.; Martin, S.; Roeck, J.; Ryder, J.; Smith, P. A new class of polymers: Starburst-dendritic macromolecules. Polym. J., 1985, 17, 117-132.
72. Sushama Telwatte, S.; Moore, K.; Johnson, A.; Tyssen, D.; Sterjovski, J.; Aldunate, M.; Gorry, P.R.; Ramsland, P.A.; Lewis, G.R.; Paull, J.R.A. Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1. Antiviral. Res., 2011, 90, 195-199.
73. Tyssen, D.; Henderson, S.A.; Johnson, A.; Sterjovski, J.; Moore, K.; La, J.; Zanin, M.; Sonza, S.; Karellas, P.; Giannis, M.P.; Krippner, G.; Wesselingh, S.; McCarthy, T.; Gorry, P.R.; Ramsland, P.A.; Cone, R.; Paull, J.R.; Lewis, G.R.; Tachedjian, G. Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS ONE 2010, 5, e12309.
74. O'Loughlin, J.; Millwood, I.Y.; McDonald, H.M.; Price, C.F.; Kaldor, J.M.; Paull, R.A. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study. Sexually Trans. Dis., 2010, 37(2), 100-104.
75. Cohen, C.R.; Brown, J.; Moscicki, A.B.; Bukusi, E.A.; Paull, J.R.; Price, C.F.; Shiboski, S. A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days. PloS One., 2011, 6(1), e16258.
76. Liang, C.H.; Chou, T.H. Effect of chain length on physicochemical properties and cytotoxicity of cationic vesicles composed of phosphatidylcholines and dialkyl-dimethylammonium bromides. Chem. Phys. Lipids, 2009, 158, 81-90.